Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald W Verhaegh

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Cancers|July 24, 2021
Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen BlockadeGerben Lassche, Yuichiro Tada, Carla M L van Herpen, et al.
International Journal of Cancer|November 21, 2019
Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patientsWim van Boxtel, Gerald W Verhaegh, Ilse A van Engen-van Grunsven, et al.
Molecular Oncology|March 2, 2021
Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatmentEmmy Boerrigter, Guillemette E Benoist, Inge M van Oort, et al.
Oncotarget|January 12, 2017
A short-term intervention with selenium affects expression of genes implicated in the epithelial-to-mesenchymal transition in the prostateDieuwertje E G Kok, Lambertus A L M Kiemeney, Gerald W Verhaegh, et al.
EJNMMI Research|July 15, 2025
The effect of androgen blockade on [<sup>68</sup>Ga]Ga-PSMA-11 and [<sup>18</sup>F]FDG PET uptake in patients with recurrent or metastatic salivary duct carcinoma: a prospective imaging studyNiels J van Ruitenbeek, Maike J M Uijen, Chantal M L Driessen, et al.
Clinical Chemistry|May 15, 2020
Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational StudyGuillemette E Benoist, Inge M van Oort, Emmy Boerrigter, et al.
Cancers|September 9, 2022
Identification of Fusion Genes and Targets for Genetically Matched Therapies in a Large Cohort of Salivary Gland Cancer PatientsGerben Lassche, Sjoerd van Helvert, Astrid Eijkelenboom, et al.
International Journal of Molecular Sciences|February 11, 2021
The Identification of Small Molecule Inhibitors That Reduce Invasion and Metastasis of Aggressive CancersArjanneke F van de Merbel, Onno van Hooij, Geertje van der Horst, et al.
Cancers|December 24, 2021
RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate CancerEmmy Boerrigter, Guillemette E Benoist, Inge M van Oort, et al.
Oncotarget|September 9, 2017
Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patientsMohammed Alshalalfa, Gerald W Verhaegh, Ewan A Gibb, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Cancers|July 24, 2021
Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen BlockadeGerben Lassche, Yuichiro Tada, Carla M L van Herpen, et al.
International Journal of Cancer|November 21, 2019
Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patientsWim van Boxtel, Gerald W Verhaegh, Ilse A van Engen-van Grunsven, et al.
Molecular Oncology|March 2, 2021
Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatmentEmmy Boerrigter, Guillemette E Benoist, Inge M van Oort, et al.
Oncotarget|January 12, 2017
A short-term intervention with selenium affects expression of genes implicated in the epithelial-to-mesenchymal transition in the prostateDieuwertje E G Kok, Lambertus A L M Kiemeney, Gerald W Verhaegh, et al.
EJNMMI Research|July 15, 2025
The effect of androgen blockade on [<sup>68</sup>Ga]Ga-PSMA-11 and [<sup>18</sup>F]FDG PET uptake in patients with recurrent or metastatic salivary duct carcinoma: a prospective imaging studyNiels J van Ruitenbeek, Maike J M Uijen, Chantal M L Driessen, et al.
Clinical Chemistry|May 15, 2020
Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational StudyGuillemette E Benoist, Inge M van Oort, Emmy Boerrigter, et al.
Cancers|September 9, 2022
Identification of Fusion Genes and Targets for Genetically Matched Therapies in a Large Cohort of Salivary Gland Cancer PatientsGerben Lassche, Sjoerd van Helvert, Astrid Eijkelenboom, et al.
International Journal of Molecular Sciences|February 11, 2021
The Identification of Small Molecule Inhibitors That Reduce Invasion and Metastasis of Aggressive CancersArjanneke F van de Merbel, Onno van Hooij, Geertje van der Horst, et al.
Cancers|December 24, 2021
RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate CancerEmmy Boerrigter, Guillemette E Benoist, Inge M van Oort, et al.
Oncotarget|September 9, 2017
Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patientsMohammed Alshalalfa, Gerald W Verhaegh, Ewan A Gibb, et al.
Pageof 6